Checkpoint blockade with programmed death-1 (PD-1) or programmed death ligand-1 (PD-L1) blocking antibodies induce tumor remissions and durable responses even upon treatment discontinuation in patients with melanoma, mismatch repair-deficient cancers, lung cancers and a variety of other malignancies [12–14]. Here, CD274 is linked to melanoma.